Cargando…
Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation
Since the rapid spread of coronavirus disease (COVID-19) became a global pandemic, healthcare ministries around the world have recommended specific control methods such as quarantining infected peoples, identifying infections, wearing mask, and practicing hand hygiene. Since no effective treatment f...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115549/ https://www.ncbi.nlm.nih.gov/pubmed/35602049 http://dx.doi.org/10.3389/fmicb.2022.757418 |
_version_ | 1784709942659252224 |
---|---|
author | Alexpandi, Rajaiah Gendrot, Mathieu Abirami, Gurusamy Delandre, Océane Fonta, Isabelle Mosnier, Joel Mariadasse, Richard Jeyakanthan, Jeyaraman Pandian, Shunmugiah Karutha Pradines, Bruno Ravi, Arumugam Veera |
author_facet | Alexpandi, Rajaiah Gendrot, Mathieu Abirami, Gurusamy Delandre, Océane Fonta, Isabelle Mosnier, Joel Mariadasse, Richard Jeyakanthan, Jeyaraman Pandian, Shunmugiah Karutha Pradines, Bruno Ravi, Arumugam Veera |
author_sort | Alexpandi, Rajaiah |
collection | PubMed |
description | Since the rapid spread of coronavirus disease (COVID-19) became a global pandemic, healthcare ministries around the world have recommended specific control methods such as quarantining infected peoples, identifying infections, wearing mask, and practicing hand hygiene. Since no effective treatment for COVID-19 has yet been discovered, a variety of drugs approved by Food and Drug Administration (FDA) have been suggested for repurposing strategy. In the current study, we predicted that doxycycline could interact with the nucleotide triphosphate (NTP) entry channel, and is therefore expected to hinder the viral replication of SARS-CoV-2 RNA-dependent RNA-polymerase (RdRp) through docking analysis. Further, the molecular dynamics results revealed that the RdRp-Doxycycline complex was structurally relatively stable during the dynamic period (100 ns), and its complex maintained close contact with their active catalytic domains of SARS-CoV-2 RdRp. The molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) calculation of binding free energy also showed that the doxycycline has worthy affinities with SARS-CoV-2 RdRp. As expected, doxycycline effectively inhibited the viral replication of IHU strains of SARS-CoV-2 (IHUMI-3 and IHUMI-6), identified from the hospitalized patients in IHU Méditerranée Infection (IHUMI), Marseille, France. Moreover, doxycycline inhibited the viral load in vitro at both on-entry and after viral entry of IHU variants of SARS-CoV-2. The results suggest that doxycycline exhibits strains-dependant antiviral activity against COVID-19. As a result, the current study concludes that doxycycline may be more effective in combination with other drugs for better COVID-19 treatment efficacy. |
format | Online Article Text |
id | pubmed-9115549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91155492022-05-19 Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation Alexpandi, Rajaiah Gendrot, Mathieu Abirami, Gurusamy Delandre, Océane Fonta, Isabelle Mosnier, Joel Mariadasse, Richard Jeyakanthan, Jeyaraman Pandian, Shunmugiah Karutha Pradines, Bruno Ravi, Arumugam Veera Front Microbiol Microbiology Since the rapid spread of coronavirus disease (COVID-19) became a global pandemic, healthcare ministries around the world have recommended specific control methods such as quarantining infected peoples, identifying infections, wearing mask, and practicing hand hygiene. Since no effective treatment for COVID-19 has yet been discovered, a variety of drugs approved by Food and Drug Administration (FDA) have been suggested for repurposing strategy. In the current study, we predicted that doxycycline could interact with the nucleotide triphosphate (NTP) entry channel, and is therefore expected to hinder the viral replication of SARS-CoV-2 RNA-dependent RNA-polymerase (RdRp) through docking analysis. Further, the molecular dynamics results revealed that the RdRp-Doxycycline complex was structurally relatively stable during the dynamic period (100 ns), and its complex maintained close contact with their active catalytic domains of SARS-CoV-2 RdRp. The molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) calculation of binding free energy also showed that the doxycycline has worthy affinities with SARS-CoV-2 RdRp. As expected, doxycycline effectively inhibited the viral replication of IHU strains of SARS-CoV-2 (IHUMI-3 and IHUMI-6), identified from the hospitalized patients in IHU Méditerranée Infection (IHUMI), Marseille, France. Moreover, doxycycline inhibited the viral load in vitro at both on-entry and after viral entry of IHU variants of SARS-CoV-2. The results suggest that doxycycline exhibits strains-dependant antiviral activity against COVID-19. As a result, the current study concludes that doxycycline may be more effective in combination with other drugs for better COVID-19 treatment efficacy. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9115549/ /pubmed/35602049 http://dx.doi.org/10.3389/fmicb.2022.757418 Text en Copyright © 2022 Alexpandi, Gendrot, Abirami, Delandre, Fonta, Mosnier, Mariadasse, Jeyakanthan, Pandian, Pradines and Ravi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Alexpandi, Rajaiah Gendrot, Mathieu Abirami, Gurusamy Delandre, Océane Fonta, Isabelle Mosnier, Joel Mariadasse, Richard Jeyakanthan, Jeyaraman Pandian, Shunmugiah Karutha Pradines, Bruno Ravi, Arumugam Veera Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation |
title | Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation |
title_full | Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation |
title_fullStr | Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation |
title_full_unstemmed | Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation |
title_short | Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation |
title_sort | repurposing of doxycycline to hinder the viral replication of sars-cov-2: from in silico to in vitro validation |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115549/ https://www.ncbi.nlm.nih.gov/pubmed/35602049 http://dx.doi.org/10.3389/fmicb.2022.757418 |
work_keys_str_mv | AT alexpandirajaiah repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT gendrotmathieu repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT abiramigurusamy repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT delandreoceane repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT fontaisabelle repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT mosnierjoel repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT mariadasserichard repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT jeyakanthanjeyaraman repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT pandianshunmugiahkarutha repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT pradinesbruno repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation AT raviarumugamveera repurposingofdoxycyclinetohindertheviralreplicationofsarscov2frominsilicotoinvitrovalidation |